Expansion of lymphokine-activated killer cells for clinical use utilizing a novel culture device

This publication has 11 references indexed in Scilit:

• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings
  JAMA, 1986
• Lymphokine-activated killer cells. Analysis of progenitors and effectors.
  The Journal of Experimental Medicine, 1986
• The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
  The Journal of Immunology, 1985
• Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
  The Journal of Immunology, 1985
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .4. LYSIS OF FRESH AND CULTURED AUTOLOGOUS TUMOR BY HUMAN-LYMPHOCYTES CULTURED IN T-CELL GROWTH-FACTOR
  1981
• The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.
  The Journal of Immunology, 1980